MiRNA Sequencing and Assay Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global MiRNA Sequencing and Assay Market is projected to expand from USD 24.26 Billion in 2025 to USD 35.56 Billion by 2031, reflecting a CAGR of 6.58%. These genomic technologies encompass methods designed to detect and quantify small non-coding RNA molecules that play a crucial role in regulating gene expression. This market trajectory is primarily driven by the increasing prevalence of chronic conditions, particularly cancer, which creates a strong demand for advanced biomarker discovery tools essential for early diagnosis and patient stratification. Additionally, the broader implementation of precision medicine initiatives and increased funding for genomic research provide substantial momentum for the sector's growth.

Despite these favorable drivers, the industry faces significant hurdles regarding the standardization of analytical protocols, a factor that complicates data reproducibility across various platforms. This technical variability presents a major challenge to widespread clinical adoption and the acquisition of regulatory approval. The critical need for these diagnostic capabilities is highlighted by the American Cancer Society, which estimated that approximately 2,001,140 new cancer cases would occur in the United States in 2024. Consequently, resolving consistency issues is vital to meeting the urgent demand for diagnostics capable of addressing the rising cancer burden.

Market Drivers

The growth of the Global MiRNA Sequencing and Assay Market is largely propelled by the rising global incidence of cancer and chronic diseases, which intensifies the need for non-invasive biomarkers facilitating early detection and patient monitoring. MiRNAs are increasingly utilized in diagnostic workflows due to their stability in biological fluids, helping to improve clinical outcomes. This escalating demand is underscored by the World Health Organization's International Agency for Research on Cancer; in a February 2024 press release titled 'Global cancer burden growing,' the agency predicted over 35 million new cancer cases in 2050, a 77% increase from 2022 levels. Such projections highlight the necessity for scalable sequencing solutions capable of managing high-volume diagnostic screening for complex pathologies.

Simultaneously, a surge in public and private funding for genomic research is accelerating the advancement of liquid biopsy-based diagnostics. This capital influx allows biotechnology firms to refine assay sensitivity and validate clinical utility, effectively reducing barriers to market entry. For instance, in a February 2024 announcement titled 'Freenome Raises $254 Million to Advance Early Cancer Detection,' Freenome reported securing $254 million to extend its screening platform's reach. Furthermore, technological scalability is a key component of this ecosystem, as evidenced by Illumina's 2024 report of shipping 352 NovaSeq X instruments during the prior fiscal year, indicating a robust industrial capacity to support the increasing throughput demands of modern genomic assays.

Market Challenges

A significant barrier to the progression of the global miRNA sequencing and assay market is the lack of standardized analytical protocols. Because laboratories employ varying workflows, extraction methods, and sequencing platforms, the resulting data frequently lacks consistency. This technical variability makes it difficult to reproduce results, which is a fundamental requirement for clinical acceptance, and prevents stakeholders from effectively comparing findings across different studies. Consequently, healthcare providers often hesitate to adopt these assays for routine patient care, stalling widespread integration.

This fragmentation also directly impacts regulatory outcomes and commercial viability, as regulatory bodies require robust evidence of analytical validity. Inconsistent data significantly delays the approval process for new diagnostic tools, restricting the availability of reliable tests needed to support modern therapeutic approaches. The urgency of this issue is highlighted by the Personalized Medicine Coalition, which reported in 2024 that personalized medicines accounted for 35 percent of all new drug approvals in 2023. The inability to standardize testing for such therapies limits revenue potential and hampers the overall expansion of the miRNA sequencing landscape.

Market Trends

The integration of artificial intelligence into miRNA biomarker discovery is fundamentally reshaping the market by facilitating the rapid identification of complex disease signatures that traditional analytical methods often miss. Advanced algorithms can now process extensive multi-omics datasets to predict miRNA targets with high precision, accelerating the development of diagnostic panels.

This technological shift is actively supported by major computing firms providing the necessary infrastructure; for instance, in a March 2024 press release titled 'NVIDIA Healthcare Launches Generative AI Microservices to Advance Drug Discovery, MedTech and Digital Health,' NVIDIA introduced over two dozen new microservices to deploy generative AI models across healthcare enterprises. These tools enable researchers to efficiently analyze genomic data and significantly reduce the time required to validate potential miRNA candidates for clinical applications.

Concurrently, the increasing adoption of single-cell miRNA sequencing is driving market expansion by resolving the cellular heterogeneity that bulk sequencing often obscures. This granular approach is particularly vital in oncology, where understanding the specific miRNA profiles of distinct cell populations within a tumor microenvironment is essential for developing targeted therapies.

Manufacturers are facilitating this shift by releasing cost-effective platforms that lower financial barriers; highlighting this trend, 10x Genomics confirmed in its October 2024 'Third Quarter 2024 Financial Results' announcement the shipping of its GEM-X Flex and Universal Multiplex assays, which enable researchers to run millions of cells for less than one cent per cell. Such innovations are critical for transitioning single-cell profiling from niche academic research to broader clinical utility.

Key Players Profiled in the MiRNA Sequencing and Assay Market

• Thermo Fisher Scientific, Inc.
• Illumina, Inc.
• QIAGEN N.V.
• PerkinElmer, Inc.
• Abcam PLC
• New England Biolabs, Inc.
• Takara Bio USA Inc.
• Lexogen GmbH
• Norgen Biotek Corp.
• Maravai LifeSciences Holdings, Inc.

Report Scope

In this report, the Global MiRNA Sequencing and Assay Market has been segmented into the following categories:

MiRNA Sequencing and Assay Market, by Technology:

• Sequencing by Synthesis
• Sequencing by Oligonucleotide Ligation and Detection (SOLiD)
• Nanopore Sequencing
• Sanger Sequencing
• Single Molecule Real-time (SMRT) Sequencing

MiRNA Sequencing and Assay Market, by Application:

• Cancer
• Polyglutamine Diseases
• Autoimmune Disease
• Schizophrenia
• Others

MiRNA Sequencing and Assay Market, by End-use:

• Pharmaceutical & Biotechnology Industry
• Research and Academic Institutes
• Others

MiRNA Sequencing and Assay Market, by Workflow:

• Library Preparation
• Sequencing
• Data Analysis & Storage

MiRNA Sequencing and Assay Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global MiRNA Sequencing and Assay Market.

Available Customization

The analyst offers customization according to your specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.